Table 1.
Characteristics of the participants in relation to whether they had optimal or sub-optimal blood pressure control.
|
Demographic
and clinical characteristics |
Blood pressure (BP) (n = 1,293) | P-value | |
|---|---|---|---|
| Optimal BP ≤140/90 mmHg | Sub-optimal BP SBP >140 or DBP >90 mmHg | ||
| N | 475 | 818 | |
| Age (years) | 73.3 (68.7–77.7) | 73.4 (69.6–77.5) | 0.23 |
| Initial AAA diameter (mm) | 37.0 (33.0–42.0) |
34.6 (31.1–40.0) | <0.001 |
| Sex | <0.001 | ||
| Male | 404 (85.1%) | 773 (94.5%) | |
| Female | 71 (14.9%) | 45 (5.5%) | |
| BMI (kg/m2) | 27.0 (25.0–30.0) |
27.0 (25.0–30.0) | 0.95 |
| Smoking | <0.001 | ||
| Never | 105 (22.1%) | 338 (41.3%) | |
| Ever | 370 (77.9%) | 480 (58.7%) | |
| eGFR | 68.5 (54.6–82.5) | 68.7 (55.9–81.3) | 0.94 |
| DM | 100 (21.1%) | 122 (14.9%) | <0.01 |
| Hypertension | 320 (67.4%) | 513 (62.7%) | 0.09 |
| IHD | 249 (52.4%) | 325 (39.8%) | <0.001 |
| Stroke | 50 (10.5%) | 56 (6.8%) | 0.02 |
| Medications | |||
| Aspirin | 261 (54.9%) | 305 (37.3%) | <0.001 |
| Other antiplatelets | 55 (11.6%) | 74 (9.0%) | 0.14 |
| CCB | 87 (18.3%) | 128 (15.6%) | 0.21 |
| Frusemide | 45 (9.5%) | 49 (6.0%) | 0.02 |
| Beta blocker | 147 (30.9%) | 172 (21.0%) | <0.001 |
| ACE I | 152 (32.0%) | 204 (24.9%) | <0.01 |
| ARB | 78 (16.4%) | 111 (13.6%) | 0.16 |
| Diuretics | 48 (10.1%) | 49 (6.0%) | <0.01 |
| Statins | 279 (58.7%) | 329 (40.2%) | <0.001 |
| Fibrates | 12 (2.5%) | 5 (0.6%) | <0.01 |
| Metformin | 48 (10.1%) | 57 (7.0%) | 0.05 |
| Other hypoglycemic agents | 39 (8.2%) | 41 (5.0%) | 0.02 |
| Follow-up (years) | 2.8 (1.2–5.0) | 4.0 (2.0–5.6) | <0.001 |
The data were expressed as median (IQR) for continuous data and n (%) for categorical data. AAA, Abdominal aortic aneurysm; ACE I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, Body mass index; CCB, Calcium channel blocker, CHD, coronary heart disease; DBP, diastolic blood pressure, DM, Diabetes mellitus; SBP, systolic blood pressure; Missing data: BMI - 15, eGFR - 393.